ATLASVistagen Therapeutics (VTGN) earnings date: Nov 12, 2026
Vistagen Therapeutics (VTGN) reports earnings for the quarter ended Sep 30, 2026 on Thu, Nov 12, 2026, before the open. Analysts expect EPS of -$0.37.
Source: company filings and exchange data · Updated Nov 2, 2026
ATLAS view on VTGN
| Last price | $0.17 (-0.4%) |
|---|---|
| Normal 1-day range (±1σ) | ±5.8% |
| Earnings beat history | Beat the EPS estimate in 3 of the last 4 reports |
These figures come from the same calibrated model and valuation as the Vistagen Therapeutics stock page. They describe an ordinary period, not the earnings reaction itself, which is usually wider and can go either way.
Vistagen Therapeutics reports on Nov 12, 2026. One email the day before, with ATLAS’s read on Vistagen Therapeutics. You can switch it off at any time.
Alert me before VTGN reportsFree to start. Creating an account takes under a minute.
Notify me when Vistagen Therapeutics reports
Track VTGN free Add Vistagen Therapeutics to a free ATLAS watchlist and see its next report date in one place.
VTGN earnings at a glance
| Next report (confirmed) | Thu, Nov 12, 2026 |
|---|---|
| Time | Before the open |
| Period | Quarter ended Sep 30, 2026 |
| EPS estimate | -$0.37 |
| Last report | Aug 14, 2026 · Beat |
| Beat rate (last 4 reports) | 3 of 4 (75%) |
| Average EPS surprise | -2.4% |
| Average move around a report | ±9.0% (last 4) |
| Sector | Healthcare · Biotechnology |
Vistagen Therapeutics earnings history: last 4 reports
Vistagen Therapeutics last reported on Aug 14, 2026: EPS of -$0.30 against an estimate of -$0.36 (+16.7% surprise), a beat.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Aug 14, 2026 | -$0.36 | -$0.30 | +16.7% | Beat | -3.7% |
| Jun 15, 2026 | -$0.27 | -$0.37 | -37.0% | Miss | +19.0% |
| Feb 12, 2026 | -$0.48 | -$0.45 | +6.3% | Beat | -10.5% |
| Jan 16, 2026 | $4.47 | $4.67 | +4.5% | Beat | -3.0% |
*Move: change in the closing price from the last close before the report day to the close the day after it, so it captures the reaction whether the company reported before the open or after the close.
Get the full ATLAS analysis for VTGN
See the fair value, the probability range and the earnings history of Vistagen Therapeutics on its ATLAS page.
Vistagen Therapeutics (VTGN) stock analysisPlans from €3.99 a month.
Vistagen Therapeutics earnings: frequently asked questions
When does Vistagen Therapeutics (VTGN) report earnings?
Vistagen Therapeutics is scheduled to report on Thursday, November 12, 2026, before the open. ATLAS only shows a confirmed date when the company or the exchange data provides one; check the investor relations page for the call details.
What is the EPS estimate for VTGN?
The consensus EPS estimate for the quarter ended Sep 30, 2026 is -$0.37 per share (USD). Estimates can change before the report.
How often does VTGN beat earnings estimates?
Of its last 4 reports with a recorded result, Vistagen Therapeutics beat the EPS estimate 3 times; the average surprise was -2.4%. Past results do not predict the next one.
How much does VTGN move around earnings?
Over its last 4 reports the stock moved an average of 9.0% (absolute, from the close before the report day to the close after it), and finished higher 1 of 4 times.
Did Vistagen Therapeutics beat earnings estimates last quarter?
Vistagen Therapeutics last reported on Aug 14, 2026: EPS of -$0.30 against an estimate of -$0.36 (+16.7% surprise), a beat.
How much does VTGN usually move in a day?
On a normal trading day the ATLAS model puts VTGN’s one-day range at about ±5.8%, with a 49% chance of closing higher. This is not an options-implied earnings move; earnings days are usually wider.
Also reporting on Thu, Nov 12, 2026
Educational information, not investment advice. Disclaimer